Western General Hospital

Running trials

• Recruiting

  Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT07665515· Phase 1· Source

• Not yet recruiting

  Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal

  NCT07341126· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  Sixth Generation High-sensitivity Cardiac Troponin T for the Early Rule Out of Myocardial Infarction: a Controlled Before and After Study

  NCT07636642· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Phase 2/3· Source

• Recruiting

  Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

  NCT07219459· Phase 2· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Source

• Recruiting

  Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

  NCT07053800· Phase 2· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

  NCT05770544· Phase 2/3· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  NCT06976203· Phase 3· Source

• Recruiting

  Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

  NCT07049926· Phase 1/2· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· Phase 3· Source

• Recruiting

  Ambroxol to Slow Progression in Parkinson Disease

  NCT05778617· Phase 3· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

  NCT06807424· Phase 3· Source

• Recruiting

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· Phase 3· Source

• Recruiting

  Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

  NCT06382948· Phase 3· Source

• Recruiting

  Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

  NCT06465953· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

  NCT06988475· Phase 2/3· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· Source

• Active, not recruiting

  Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

  NCT06449222· Phase 2· Source

• Recruiting

  VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

  NCT06257706· Phase 4· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Source

• Recruiting

  SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

  NCT05990192· Phase 2· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Source

• Active, not recruiting

  Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06158841· Phase 3· Source

• Active, not recruiting

  A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

  NCT06294925· Source

• Active, not recruiting

  A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

  NCT06307431· Phase 2· Source

• Active, not recruiting

  Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

  NCT06151574· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

  NCT05770037· Phase 2/3· Source

• Recruiting

  A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  NCT06131840· Phase 1· Source

• Recruiting

  DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

  NCT05770102· Phase 2/3· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers10 recruiting
• Colorectal cancer8 recruiting
• Lung cancer7 recruiting
• Multiple myeloma7 recruiting
• Ovarian cancer7 recruiting
• Kidney cancer5 recruiting
• Melanoma5 recruiting
• Pancreatic cancer4 recruiting
• Crohn's disease3 recruiting
• Gastric and esophageal cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Acute myeloid leukemia2 recruiting
• Endometrial cancer2 recruiting
• Head and neck cancer2 recruiting
• HIV2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lupus (SLE)2 recruiting
• Myelodysplastic syndromes2 recruiting
• Neuroblastoma2 recruiting
• Thyroid cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alzheimer disease1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Coronary artery disease1 recruiting
• Hepatitis B1 recruiting
• Neuroendocrine tumours1 recruiting
• Parkinson disease1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

  NCT06028438· Phase 2· Source

• Terminated

  Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

  NCT04854096· Phase 2· Source

• Completed

  A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

  NCT05361434· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

  NCT04660344· Phase 3· Source

• Completed

  Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

  NCT04776148· Phase 3· Source

• Terminated

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· Phase 1· Source

• Completed

  Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

  NCT04742101· Phase 1/2· Source

• Terminated

  Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

  NCT04796324· Phase 2· Source

• Completed

  Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

  NCT04440592· Phase 2· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Source

• Completed

  AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

  NCT04006405· Source

• Completed

  Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

  NCT03945773· Phase 2· Source

• Completed

  A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

  NCT03981146· Phase 2· Source

• Completed

  Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

  NCT03976323· Phase 3· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

  NCT03976362· Phase 3· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Source

• Completed

  Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

  NCT03884101· Phase 3· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986· Phase 3· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Source

• Completed

  Study to Evaluate CCS1477 in Advanced Tumours

  NCT03568656· Phase 1/2· Source

• Completed

  A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

  NCT03371017· Phase 3· Source

• Completed

  Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  NCT03260894· Phase 3· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Source

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Source

• Completed

  A Phase I Trial of LY3143921 Hydrate in Solid Tumours

  NCT03096054· Phase 1· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

  NCT03142334· Phase 3· Source

• Completed

  Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

  NCT02733159· Phase 2· Source

• Completed

  National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

  NCT02664935· Phase 2· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Source

• Completed

  Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

  NCT01726374· Phase 3· Source

Trial sites

• Edinburgh Cancer Centre, Western General Hospital12 trials
• The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research Centre1 trial
• Western General Hospital100 trials
• Western General Hospital Edinburgh3 trials
• Western General Hospital, Edinburgh Cancer Centre3 trials
• Western General Hospital, Edinburgh, EH4 2XU1 trial
• Western General Hospital, Edinburgh (Site 1924)2 trials
• Western General Hospital - Haematology1 trial
• Western General Hospital /ID# 2074481 trial
• Western General Hospital /ID# 2611061 trial
• Western General Hospital /ID# 2663331 trial
• Western General Hospital, Lothian Health Board2 trials
• Western General Hospital (Site 0121)1 trial
• Western General Hospital (Site 0749)1 trial
• Western General Hospital (Site 1003)1 trial
• Western General Hospital (Site 1400)1 trial
• Western General Hospital (Site 1401)1 trial
• Western General Hospital (Site 1402)1 trial
• Western General Hospital (Site 1411)1 trial
• Western General Hospital (Site 1600)1 trial
• Western General Hospital (Site 1806)1 trial
• Western General Hospital (Site 1912)1 trial
• Western General Hospital (Site 2607)1 trial
• Western General Hospital (Site 2608)1 trial
• Western General Hospital (Site 2806)1 trial
• Western General Hospital (Site 3402)1 trial
• Western General Hospital (Site 3604)1 trial
• Western General Hospital (Site 4012)1 trial
• Western General Hospital (Site 5402)1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Crohn's disease28 works · 4 trials